1. Pink Sheet
  2. >>Geography
  3. >>Europe

World First For Advicenne’s Rare Kidney Disease Drug On The Cards

ADV7103 Could Become The First Approved Treatment For Distal Renal Tubular Acidosis

 
• By Neena Brizmohun

Advicenne should soon find out whether the European Medicines Agency will give its product, ADV7103, the thumbs up. Approval then wouldn’t be far off.

World Kidney Day concept: healthcare symbolic design
Distal renal tubular acidosis affects around 30,000 patients in Europe • Source: Shutterstock

The European Medicines Agency is this week deciding whether to recommend pan-EU approval for ADV7103, the investigational drug that Advicenne is developing to treat the rare kidney disease, distal renal tubular acidosis (dRTA).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.